Good find. Only question I have is how much the rising dollar is going to hurt profit. Not sure Srx can simply raise prices as they are negotiated with the respective health funding bodies. The large studies are quite some time off unfortunately. I wonder if this will become a TO target ahead of those results. I'll be a buyer on weakness.
